Trials / Unknown
UnknownNCT04560244
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
Director of Shandong Cancer Hospital and Institute
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Shandong Cancer Hospital and Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single center, single arm, open study design. The main purpose of this study is to evaluate the tolerance and efficacy of SHR1701 with synchronous radiotherapy in patients with metastatic non-small cell lung cancer who have failed after systematic treatment. Large fraction radiotherapy is given to all lesions as much as possible, and low-dose radiotherapy is given to the lesions that cannot be tolerated or have no obvious benefit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1701 | PD-L1 / TGF-β RII double antibody |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-09-01
- Completion
- 2022-12-01
- First posted
- 2020-09-23
- Last updated
- 2020-09-23
Source: ClinicalTrials.gov record NCT04560244. Inclusion in this directory is not an endorsement.